Claims for Patent: 10,149,848

Summary for Patent: 10,149,848

Title:	Method for the treatment of bladder cancer
Abstract:	Methods of treating bladder cancer using terconazole are disclosed herein. Terconazole can be administered as part of a comprehensive treatment program, which can also include chemotherapy, immunotherapy, radiation therapy and/or surgical treatment.
Inventor(s):	Malhotra; Geena (Mumbai, IN), Joshi; Kalpana (Maharashtra, IN)
Assignee:	Cipla Limited (Mumbai, IN)
Application Number:	15/370,393
Patent Claims:	1. A method for the treatment of bladder cancer in a patient, the method comprising administering to said patient terconazole, or a pharmaceutically acceptable salt thereof, in an amount effective to treat bladder cancer, wherein the patient is diagnosed with Stage 0, Stage I, Stage II, Stage III or Stage IV bladder cancer, wherein the terconazole is administered as a single agent or in combination with an anti-cancer agent selected from the group consisting of oncolytic viruses, monoclonal antibodies, microtubule inhibitors, topoisomerase inhibitors, platins, alkylating agents, and antimetabolites. 2. The method according to claim 1, wherein the patient also receives surgical or radiation therapy. 3. The method according to claim 1, wherein the patient also receives Bacillus Calmette-Guerin vaccine. 4. The method according to claim 3, wherein terconazole is administered subsequent to Bacillus Calmette-Guerin vaccine delivery. 5. The method according to claim 1, wherein terconazole is administered in combination with an immunotherapy comprising a monoclonal antibody or a oncolytic virus. 6. The method according to claim 3, wherein the surgery comprises transurethral resection of bladder tumor (TURBT), partial or radical cystectomy. 7. The method according to claim 6, wherein terconazole is administered subsequent to surgical treatment for bladder cancer. 8. The method according to claim 6, wherein terconazole is administered prior to the surgical treatment for bladder cancer. 9. The method according to claim 1, wherein the anti-cancer agent comprises a platin compound. 10. The method according to claim 9, wherein platin compound comprises cisplatin, carboplatin, oxaliplatin, or nedaplatin. 11. The method according to claim 10, wherein platin compound is cisplatin. 12. A kit comprising terconazole and at least one anti-cancer agent comprising one or more monoclonal antibodies, oncolytic viruses, microtubule inhibitors, topoisomerase inhibitors, platins, alkylating agents, or anti-metabolites.

Details for Patent 10,149,848

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	06/21/1989		2035-12-09